Search
for
Sort by
Research 30 of 1000+
- SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss
- Using artificial intelligence to compute Severity of Alopecia Tool scores
- Alopecia Universalis Treated with Ayurveda Protocol and Assessed by SALT (Severity of Alopecia Tool) - A Case Report
- Development of a Visual Extension of the Severity of Alopecia Tool (VESALT) for Alopecia Areata
- Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial
- Two‐dimensional planimetry for alopecia areata severity evaluation compared with severity of alopecia tool: A pilot study
- Using qualitative methods to establish the clinically meaningful threshold for treatment success for the Severity of Alopecia Tool (SALT) score
- STRIAA (Severity TRichoscopy Index Alopecia Areata): Validation of a Novel Trichoscopic Tool for Evaluation of Alopecia Areata
- 125: Individual Severity of Alopecia Tool (SALT) score trajectories of roll-over adolescent patients with alopecia areata (AA) treated with ritlecitinib in the ongoing long-term, open-label, phase 3 ALLEGRO-LT study
- 33766 Efficacy of baricitinib in patients with various degrees of alopecia areata severity: Results from BRAVE-AA1 and BRAVE-AA2
- Reply to: “Serum vitamin D level and disease severity of alopecia areata: A meta-regression analysis”
- Assessment of Alopecia Areata Disease Severity in Pediatric Patients
- A consensus-based treatment algorithm for alopecia areata in adolescents and adults: integrating severity, quality of life, and disease dynamics
- Generative Artificial Intelligence Tools: Evaluating Ways to Automate Your SALT ( GATEWAYS ) Scoring of Alopecia Areata
- Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
- BH15 The burden of alopecia areata: examining baseline health-related quality of life and clinical assessment tools
- Alopecia areata. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Part 1. Diagnosis and severity assessment
- Estimation of Claudin 3 in the Sreum of Alopecia Areata Patients and Its Association with Disease Severity
- 1315 An Integrated model of alopecia areata biomarkers highlights both Th1/Th2 upregulation, with stronger correlations between Th2 activation and disease severity
- 15 Evaluation of several hematological and inflammatory parameters in patients with alopecia areata and their correlation with disease severity
- ASSESSMENT OF THE SEVERETY OF ANDROGENETIC ALOPECIA USING TRICHOSCOPIC FEATURES AND THEIR CORRELATION WITH HISTOMORPHOLOGICAL FINDINGS
- Serum level of retinol-binding protein 4 in alopecia areata: relation with recurrence and severity
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
- Management of alopecia areata: Updates and algorithmic approach
- Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety